Lindbrook Capital, LLC Catalyst Pharmaceuticals, Inc. Transaction History
Lindbrook Capital, LLC
- $1.18 Billion
- Q3 2024
A detailed history of Lindbrook Capital, LLC transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Lindbrook Capital, LLC holds 140 shares of CPRX stock, worth $3,089. This represents 0.0% of its overall portfolio holdings.
Number of Shares
140
Previous 140
-0.0%
Holding current value
$3,089
Previous $2,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding CPRX
# of Institutions
327Shares Held
94.6MCall Options Held
19.1KPut Options Held
51.1K-
Black Rock Inc. New York, NY18.7MShares$413 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.04MShares$177 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY6.23MShares$137 Million2.3% of portfolio
-
State Street Corp Boston, MA5.69MShares$125 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.02MShares$66.6 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.27B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...